StockData
BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc. (BBIO) stock

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30
$77.36−0.94 (-1.20%)

Close on Nov 16, 2026Market cap $15.07BP/E –Yield –

BridgeBio Pharma total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

BridgeBio Pharma's total debt was $0 at Jun 30, 2025. For fiscal 2024 it was $437.34M, down 2.0% from the year before. The highest annual figure on record is $446.45M in fiscal 2023.

Annual total debt

PeriodPeriod endValueChange
FY2024Dec 31, 2024$437.34M-2.0%
FY2023Dec 31, 2023$446.45M+3.6%
FY2022Dec 31, 2022$430.99M+0.1%
FY2021Dec 31, 2021$430.75M+358.8%
FY2020Dec 31, 2020$93.88M+2.3%
FY2019Dec 31, 2019$91.79M+68.4%
FY2018Dec 31, 2018$54.51M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$0-100.0%
Q4 FY2024Dec 31, 2024$437.34M-2.0%
Q3 FY2024Sep 30, 2024$436.22M-1.2%
Q2 FY2024Jun 30, 2024$435.45M-1.1%
Q1 FY2024Mar 31, 2024$434.72M-0.2%
Q4 FY2023Dec 31, 2023$446.45M+3.6%
Q3 FY2023Sep 30, 2023$441.72M+1.8%
Q2 FY2023Jun 30, 2023$440.50M+2.3%
Q1 FY2023Mar 31, 2023$435.76M+322.5%
Q4 FY2022Dec 31, 2022$430.99M+320.0%
Q1 FY2022Mar 31, 2022$434.11M+359.8%
Q4 FY2021Dec 31, 2021$430.75M+358.8%
Q3 FY2021Sep 30, 2021$103.14M+10.4%
Q2 FY2021Jun 30, 2021$102.61M+10.4%
Q1 FY2021Mar 31, 2021$94.41M+2.2%
Q4 FY2020Dec 31, 2020$93.88M+2.3%
Q3 FY2020Sep 30, 2020$93.39M+24.5%
Q2 FY2020Jun 30, 2020$92.91M+70.5%
Q1 FY2020Mar 31, 2020$92.42M–
Q4 FY2019Dec 31, 2019$91.79M–
Q3 FY2019Sep 30, 2019$75.02M–
Q4 FY2018Dec 31, 2018$54.51M–

More BridgeBio Pharma figures

See a number that looks wrong?